Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Down 76.0% in July

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 429,600 shares, a decline of 76.0% from the June 30th total of 1,790,000 shares. Based on an average trading volume of 1,480,000 shares, the short-interest ratio is currently 0.3 days. Approximately 2.5% of the company’s stock are short sold.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals stock traded down $0.03 during mid-day trading on Friday, reaching $0.55. 1,881,410 shares of the stock traded hands, compared to its average volume of 3,504,322. The business’s 50-day moving average is $2.25 and its 200-day moving average is $6.50. Tonix Pharmaceuticals has a 12-month low of $0.46 and a 12-month high of $58.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.47 and a quick ratio of 0.87. The stock has a market capitalization of $1.64 million, a PE ratio of 0.00 and a beta of 2.12.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Monday, May 13th. The company reported ($5.76) EPS for the quarter, beating analysts’ consensus estimates of ($16.64) by $10.88. The business had revenue of $2.48 million for the quarter, compared to analysts’ expectations of $4.00 million. As a group, sell-side analysts predict that Tonix Pharmaceuticals will post -34.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC raised its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,770,000 shares of the company’s stock after purchasing an additional 2,320,000 shares during the period. Armistice Capital LLC owned 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent SEC filing. Institutional investors own 82.26% of the company’s stock.

Wall Street Analysts Forecast Growth

TNXP has been the subject of several analyst reports. StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Friday, June 14th. They set a “sell” rating for the company. Alliance Global Partners lifted their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.